search
Back to results

Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 3
Locations
Russian Federation
Study Type
Interventional
Intervention
Insulin Humulin® NPH
Insulin Rinsulin® NPH
Sponsored by
Geropharm
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring diabetes mellitus, insulin

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Signed written consent
  • Diabetes mellitus type 2
  • Indications for Rinsulin NPH / Humalog NPH treatment
  • Glycosylated hemoglobin (HbA1c) level of 6.5 to 12.0 % at screening (both values inclusive)
  • Body mass index (BMI) of 18.0 to 35 kg/m2 at screening (both values inclusive).
  • Female patients of childbearing potential who are willing to use two acceptable methods of contraception, (e.g., intra-uterine device plus condom, spermicidal gel plus condom, diaphragm plus condom, etc.), from the time of screening and for the duration of the trial, through trial completion.

Exclusion Criteria:

  • Age less than 18 years old at screening
  • Pregnant and breast-feeding women
  • Need of administration of glucocorticoid therapy or any other therapy that may influence glucose level
  • Administration of any immunosupressive drugs (Cyclosporinum, Methotrexatum)
  • Serological evidence of human immunodeficiency virus (HIV), hepatitis B (HbSAg), hepatitis C (HCVAb) or antibodies to Treponema pallidum (syphilis) at screening.
  • History of hypersensitivity to any of the active or inactive ingredients of the insulin/insulin analogue preparations used in the trial, OR history of significant allergic drug reactions.
  • History of hematological disorders that can affect the reliability of HbA1c estimation (hemoglobinopathies, hemolytic anemia, etc.).
  • History or presence of a medical condition or disease that in the investigator's opinion would embarrass glycemic control and completion of the study
  • Presence of severe diabetes complications
  • Receipt of another investigational drug in the 3 months prior to screening
  • Acute psychiatric disorder or exacerbation of chronic psychiatric disorder at screening
  • History or presence of drug abuse
  • Positive test for addictive substance in urine at screening

Sites / Locations

  • Chelyabinsk Railway Clinical Hospital
  • Moscow Endocrinological Dispensary
  • Moscow Clinical Hospital № 71
  • Nizhny Novgorod Regional Clinical Hospital
  • V.A. Baranov Republic Hospital
  • City Polyclinic № 6
  • City Hospital № 2
  • City Polyclinic № 17
  • Medical Sanitary Unit № 157
  • Institute of Medical Research
  • Research Center Eco-Safety
  • Saint Petersburg State Diagnostic Center № 85
  • Diabetes Center
  • Clinical Hospital № 3

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Insulin Humulin® NPH

Insulin Rinsulin® NPH

Arm Description

Insulin Humulin® NPH twice daily, individually glucose-level based administered doses +/- 1,2 or 3 OADs in stable doses, started before enrollment

Insulin Rinsulin® NPH twice daily, individually glucose-level based administered doses +/- 1,2 or 3 OADs in stable doses, started before enrollment

Outcomes

Primary Outcome Measures

Antibody Response
Change from baseline in titer of antibodies to human insulin

Secondary Outcome Measures

Hypoglycemic episodes (glucose level < 3.9 mmol/l) frequency
Change in BMI from baseline
Occurrence of adverse events
Occurrence of Injection Site Reaction
Change in HbA1c from baseline
Change in fasting plasma glucose level from baseline
Change in fasting plasma glucose level from baseline
Change in fasting plasma glucose level from baseline
Change in basal insulin dose per body weight (U/kg) from baseline
Change in total basal insulin dose (U) from baseline

Full Information

First Posted
July 5, 2019
Last Updated
July 8, 2019
Sponsor
Geropharm
search

1. Study Identification

Unique Protocol Identification Number
NCT04012775
Brief Title
Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients
Official Title
An Open-label, Randomized, Multi-center, Parallel-group Clinical Trial Comparing the Efficacy and Safety of Rinsulin® NPH ("Geropharm", Russia) With Humulin® NPH ("Lilly France", France) in Type 2 Diabetes Mellitus Patients
Study Type
Interventional

2. Study Status

Record Verification Date
January 2019
Overall Recruitment Status
Completed
Study Start Date
April 20, 2017 (Actual)
Primary Completion Date
September 24, 2018 (Actual)
Study Completion Date
September 24, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Geropharm

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The study is designed to approve non-inferior efficacy and safety of Rinsulin® NPH compared to Humulin® NPH.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
diabetes mellitus, insulin

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
201 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Insulin Humulin® NPH
Arm Type
Active Comparator
Arm Description
Insulin Humulin® NPH twice daily, individually glucose-level based administered doses +/- 1,2 or 3 OADs in stable doses, started before enrollment
Arm Title
Insulin Rinsulin® NPH
Arm Type
Experimental
Arm Description
Insulin Rinsulin® NPH twice daily, individually glucose-level based administered doses +/- 1,2 or 3 OADs in stable doses, started before enrollment
Intervention Type
Biological
Intervention Name(s)
Insulin Humulin® NPH
Intervention Description
4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
Intervention Type
Biological
Intervention Name(s)
Insulin Rinsulin® NPH
Intervention Description
4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
Primary Outcome Measure Information:
Title
Antibody Response
Description
Change from baseline in titer of antibodies to human insulin
Time Frame
24 weeks
Secondary Outcome Measure Information:
Title
Hypoglycemic episodes (glucose level < 3.9 mmol/l) frequency
Time Frame
28 weeks (4 + 24 weeks)
Title
Change in BMI from baseline
Time Frame
24 weeks
Title
Occurrence of adverse events
Time Frame
28 weeks (4 + 24 weeks)
Title
Occurrence of Injection Site Reaction
Time Frame
28 weeks (4 + 24 weeks)
Title
Change in HbA1c from baseline
Time Frame
24 weeks
Title
Change in fasting plasma glucose level from baseline
Time Frame
4 weeks
Title
Change in fasting plasma glucose level from baseline
Time Frame
16 weeks
Title
Change in fasting plasma glucose level from baseline
Time Frame
28 weeks
Title
Change in basal insulin dose per body weight (U/kg) from baseline
Time Frame
24 weeks
Title
Change in total basal insulin dose (U) from baseline
Time Frame
24 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signed written consent Diabetes mellitus type 2 Indications for Rinsulin NPH / Humalog NPH treatment Glycosylated hemoglobin (HbA1c) level of 6.5 to 12.0 % at screening (both values inclusive) Body mass index (BMI) of 18.0 to 35 kg/m2 at screening (both values inclusive). Female patients of childbearing potential who are willing to use two acceptable methods of contraception, (e.g., intra-uterine device plus condom, spermicidal gel plus condom, diaphragm plus condom, etc.), from the time of screening and for the duration of the trial, through trial completion. Exclusion Criteria: Age less than 18 years old at screening Pregnant and breast-feeding women Need of administration of glucocorticoid therapy or any other therapy that may influence glucose level Administration of any immunosupressive drugs (Cyclosporinum, Methotrexatum) Serological evidence of human immunodeficiency virus (HIV), hepatitis B (HbSAg), hepatitis C (HCVAb) or antibodies to Treponema pallidum (syphilis) at screening. History of hypersensitivity to any of the active or inactive ingredients of the insulin/insulin analogue preparations used in the trial, OR history of significant allergic drug reactions. History of hematological disorders that can affect the reliability of HbA1c estimation (hemoglobinopathies, hemolytic anemia, etc.). History or presence of a medical condition or disease that in the investigator's opinion would embarrass glycemic control and completion of the study Presence of severe diabetes complications Receipt of another investigational drug in the 3 months prior to screening Acute psychiatric disorder or exacerbation of chronic psychiatric disorder at screening History or presence of drug abuse Positive test for addictive substance in urine at screening
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Olga A Miroshnichenko, PhD
Organizational Affiliation
Saint Petersburg State Diagnostic Center № 85
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chelyabinsk Railway Clinical Hospital
City
Chelyabinsk
ZIP/Postal Code
454000
Country
Russian Federation
Facility Name
Moscow Endocrinological Dispensary
City
Moscow
ZIP/Postal Code
119034
Country
Russian Federation
Facility Name
Moscow Clinical Hospital № 71
City
Moscow
ZIP/Postal Code
121374
Country
Russian Federation
Facility Name
Nizhny Novgorod Regional Clinical Hospital
City
Nizhny Novgorod
ZIP/Postal Code
603126
Country
Russian Federation
Facility Name
V.A. Baranov Republic Hospital
City
Petrozavodsk
ZIP/Postal Code
185000
Country
Russian Federation
Facility Name
City Polyclinic № 6
City
Saint Petersburg
ZIP/Postal Code
192148
Country
Russian Federation
Facility Name
City Hospital № 2
City
Saint Petersburg
ZIP/Postal Code
194354
Country
Russian Federation
Facility Name
City Polyclinic № 17
City
Saint Petersburg
ZIP/Postal Code
195176
Country
Russian Federation
Facility Name
Medical Sanitary Unit № 157
City
Saint Petersburg
ZIP/Postal Code
196066
Country
Russian Federation
Facility Name
Institute of Medical Research
City
Saint Petersburg
ZIP/Postal Code
196084
Country
Russian Federation
Facility Name
Research Center Eco-Safety
City
Saint Petersburg
ZIP/Postal Code
196143
Country
Russian Federation
Facility Name
Saint Petersburg State Diagnostic Center № 85
City
Saint Petersburg
ZIP/Postal Code
198260
Country
Russian Federation
Facility Name
Diabetes Center
City
Samara
ZIP/Postal Code
443067
Country
Russian Federation
Facility Name
Clinical Hospital № 3
City
Yaroslavl
ZIP/Postal Code
150007
Country
Russian Federation

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients

We'll reach out to this number within 24 hrs